vs
EyePoint, Inc.（EYPT）与因美纳（ILMN）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是EyePoint, Inc.的1783.5倍（$1.1B vs $619.0K）。因美纳净利率更高（16.8% vs -10922.3%，领先10939.1%）。因美纳同比增速更快（-1.6% vs -94.7%）。因美纳自由现金流更多（$335.0M vs $-66.0M）。过去两年因美纳的营收复合增速更高（0.8% vs -77.0%）
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
EYPT vs ILMN — 直观对比
营收规模更大
ILMN
是对方的1783.5倍
$619.0K
营收增速更快
ILMN
高出93.1%
-94.7%
净利率更高
ILMN
高出10939.1%
-10922.3%
自由现金流更多
ILMN
多$401.0M
$-66.0M
两年增速更快
ILMN
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $619.0K | $1.1B |
| 净利润 | $-67.6M | $186.0M |
| 毛利率 | — | 65.9% |
| 营业利润率 | -11364.3% | 15.8% |
| 净利率 | -10922.3% | 16.8% |
| 营收同比 | -94.7% | -1.6% |
| 净利润同比 | -63.3% | 205.7% |
| 每股收益（稀释后） | $-0.82 | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EYPTILMN
| Q4 25 | $619.0K | — | ||
| Q3 25 | $966.0K | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $24.5M | — | ||
| Q4 24 | $11.6M | $1.1B | ||
| Q3 24 | $10.5M | $1.1B | ||
| Q2 24 | $9.5M | $1.1B | ||
| Q1 24 | $11.7M | $1.1B |
净利润EYPTILMN
| Q4 25 | $-67.6M | — | ||
| Q3 25 | $-59.7M | — | ||
| Q2 25 | $-59.4M | — | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $-41.4M | $186.0M | ||
| Q3 24 | $-29.4M | $705.0M | ||
| Q2 24 | $-30.8M | $-2.0B | ||
| Q1 24 | $-29.3M | $-126.0M |
毛利率EYPTILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 65.9% | ||
| Q3 24 | 93.0% | 69.0% | ||
| Q2 24 | 85.2% | 64.8% | ||
| Q1 24 | 93.5% | 62.0% |
营业利润率EYPTILMN
| Q4 25 | -11364.3% | — | ||
| Q3 25 | -6420.8% | — | ||
| Q2 25 | -1166.8% | — | ||
| Q1 25 | -199.7% | — | ||
| Q4 24 | -390.4% | 15.8% | ||
| Q3 24 | -311.2% | 68.6% | ||
| Q2 24 | -364.5% | -147.2% | ||
| Q1 24 | -285.2% | -10.3% |
净利率EYPTILMN
| Q4 25 | -10922.3% | — | ||
| Q3 25 | -6183.4% | — | ||
| Q2 25 | -1114.3% | — | ||
| Q1 25 | -184.8% | — | ||
| Q4 24 | -357.3% | 16.8% | ||
| Q3 24 | -279.0% | 65.3% | ||
| Q2 24 | -325.3% | -178.8% | ||
| Q1 24 | -250.6% | -11.7% |
每股收益（稀释后）EYPTILMN
| Q4 25 | $-0.82 | — | ||
| Q3 25 | $-0.85 | — | ||
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.65 | — | ||
| Q4 24 | $-0.65 | $1.16 | ||
| Q3 24 | $-0.54 | $4.42 | ||
| Q2 24 | $-0.58 | $-12.48 | ||
| Q1 24 | $-0.55 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | $93.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $306.1M | $2.4B |
| 总资产 | $364.0M | $6.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EYPTILMN
| Q4 25 | $306.1M | — | ||
| Q3 25 | $204.0M | — | ||
| Q2 25 | $255.7M | — | ||
| Q1 25 | $318.2M | — | ||
| Q4 24 | $370.9M | $93.0M | ||
| Q3 24 | $253.8M | $70.0M | ||
| Q2 24 | $280.2M | $74.0M | ||
| Q1 24 | $299.3M | — |
股东权益EYPTILMN
| Q4 25 | $306.1M | — | ||
| Q3 25 | $200.2M | — | ||
| Q2 25 | $246.0M | — | ||
| Q1 25 | $298.4M | — | ||
| Q4 24 | $336.5M | $2.4B | ||
| Q3 24 | $218.7M | $2.1B | ||
| Q2 24 | $228.3M | $1.4B | ||
| Q1 24 | $249.9M | $5.7B |
总资产EYPTILMN
| Q4 25 | $364.0M | — | ||
| Q3 25 | $251.7M | — | ||
| Q2 25 | $301.1M | — | ||
| Q1 25 | $362.6M | — | ||
| Q4 24 | $418.5M | $6.3B | ||
| Q3 24 | $300.9M | $6.0B | ||
| Q2 24 | $324.2M | $6.1B | ||
| Q1 24 | $329.2M | $10.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | $364.0M |
| 自由现金流经营现金流 - 资本支出 | $-66.0M | $335.0M |
| 自由现金流率自由现金流/营收 | -10667.7% | 30.3% |
| 资本支出强度资本支出/营收 | 159.3% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.96× |
| 过去12个月自由现金流最近4个季度 | $-243.4M | $709.0M |
8季度趋势，按日历期对齐
经营现金流EYPTILMN
| Q4 25 | $-65.0M | — | ||
| Q3 25 | $-59.4M | — | ||
| Q2 25 | $-62.6M | — | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-35.8M | $364.0M | ||
| Q3 24 | $-39.0M | $316.0M | ||
| Q2 24 | $-20.2M | $80.0M | ||
| Q1 24 | $-31.2M | $77.0M |
自由现金流EYPTILMN
| Q4 25 | $-66.0M | — | ||
| Q3 25 | $-60.2M | — | ||
| Q2 25 | $-63.8M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | $335.0M | ||
| Q3 24 | $-40.6M | $284.0M | ||
| Q2 24 | $-21.1M | $49.0M | ||
| Q1 24 | $-32.4M | $41.0M |
自由现金流率EYPTILMN
| Q4 25 | -10667.7% | — | ||
| Q3 25 | -6226.9% | — | ||
| Q2 25 | -1196.5% | — | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | 30.3% | ||
| Q3 24 | -385.8% | 26.3% | ||
| Q2 24 | -222.4% | 4.4% | ||
| Q1 24 | -277.0% | 3.8% |
资本支出强度EYPTILMN
| Q4 25 | 159.3% | — | ||
| Q3 25 | 82.6% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.3% | 2.6% | ||
| Q3 24 | 15.0% | 3.0% | ||
| Q2 24 | 9.5% | 2.8% | ||
| Q1 24 | 10.2% | 3.3% |
现金转化率EYPTILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EYPT
暂无分部数据
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
